SEC Form 4 · accession 0001817199-26-000022

Nurix Therapeutics, Inc. · NRIX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Legal Officer

Period of report

Jun 25, 2026

Accepted (ET)

Jun 25, 2026 · 6:38 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001549595

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 25, 2026	M	13,333	$7.26	A	26,912	D
Common Stock	Jun 25, 2026	M	15,602	$8.72	A	42,514	D
Common Stock^F2	Jun 25, 2026	S	28,935	$20.0624	D	13,579	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F3	$7.26	Jun 25, 2026	M	13,333	D	—	Feb 26, 2030	Common Stock	13,333	0	D
Employee Stock Option (right to buy)^F4	$8.72	Jun 25, 2026	M	15,602	D	—	Feb 12, 2034	Common Stock	15,602	134,398	D

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2Represents the weighted average sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.40. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3The stock option vested as to 1/48 of the total shares monthly beginning February 18, 2020, until the option was fully vested on January 18, 2024.
F4The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027.